Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 2/20 | 0.37 |
| ▸ | TERT | O14746 | 1/20 | 0.33 |
| ▸ | APP | P05067 | 1/20 | 0.33 |
| ▸ | BACE1 | P56817 | 2/20 | 0.32 |
| ▸ | ERN1 | O75460 | 1/20 | 0.32 |
| ▸ | CCR1 | P32246 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | BLM | P54132 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2492679 | 0.84 | CCR1 (0.39) | TERTAPPERN1CCR1ALDH1A1 | |
| SCHEMBL9772995 | 0.77 | CCR1 (0.34) | TERTERN1CCR1ALDH1A1 | |
| SCHEMBL29589485 | 0.77 | CCR1 (0.34) | TERTERN1CCR1ALDH1A1 | |
| SCHEMBL1181671 | 0.75 | — | — | |
| SCHEMBL28706651 | 0.74 | NOS2 (0.41) | NOS2TERTCCR1CYP3A4BLM | |
| SCHEMBL28750609 | 0.74 | ERN1 (0.32) | ERN1CCR1ALDH1A1 | |
| SCHEMBL16983094 | 0.74 | ERN1 (0.41) | TERTAPPERN1CCR1ALDH1A1 | |
| SCHEMBL3776650 | 0.74 | CCR1 (0.37) | ERN1CCR1MAPTALDH1A1 | |
| SCHEMBL29956511 | 0.70 | HTR6 (0.36) | CCR1MAPT | |
| SCHEMBL28664997 | 0.69 | NT5E (0.38) | TERTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| US-8101621-B2 | Aminopyridine derivatives having aurora a selective inhibitory action | MSD K.K. (JP) | 2012-01-24 | — | — | US | disclosed |
| US-20090192174-A1 | Novel Aminopyridine Derivatives Having Aurora a Selective Inhibitory Action | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2009-07-30 | — | — | US | disclosed |
| US-20080027042-A1 | Novel Aminopyridine Derivatives Having Aurora a Selective Inhibitory Action | OHKUBO MITSURU | 2008-01-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090192174-A1 | Novel Aminopyridine Derivatives Having Aurora a Selective Inhibitory Action | RB1, AURKA, AURKC | NOS2 3559/4885TERT 2301/4885APP 4353/4885 |
| US-20080027042-A1 | Novel Aminopyridine Derivatives Having Aurora a Selective Inhibitory Action | AURKA, AURKC, AURKB | NOS2 2426/4885TERT 2413/4885APP 4084/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.